Statera Biopharma, Inc. (STAB) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and thank you for joining us for Satara Biopharma, Inc.' 's third quarter 2021 financial results conference call. Following the prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to Satara's Executive Vice President of Investor Relations, Nicole Auschner. Ma'am, you may now begin. Good afternoon, everyone, and thank you for joining the Satara Biopharma's 2021 third quarter financial results and corporate update call. Earlier this afternoon, Cetera Biopharma issued a press release detailing the financial results for the three and nine months ended September 30th, 2021, which we encourage listeners to read. The press release can be found in the investor section for CeteraBiopharma.com. Cetera also filed a 10-2 this afternoon, which is available on SEC.gov. Before beginning today's call, I would like to make the following statement. Today, we will be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, and the development and effectiveness of our investigational drug candidates, and our expectations regarding our capital allocation and cash resources. These statements are based on current expectations and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in our most recent 10-K filing. CETERA disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. With us on today's call is Michael K. Hanley, President and CEO of CETERA Biopharma, Inc., who ...